Table 3.

Adverse events with avagacestat or placebo

Events, n	Placebo	Avagacestat		Placebo	Avagacestat		Total placebo (n= 9)	Total Avagacestat (n= 27)
	18–59 years (n= 4)	18–45 years (n= 6)	46–59 years (n= 6)	≥60 years (n= 5)	60–74 years (n= 6)	≥75 years (n= 9)
Total subjects with AEs	1	2	1	4	3	6	5	12
Total AEs	2	2	1	9	4	6	11	13
System organ class preferred term
General disorders and administration site conditions	0	0	0	0	0	1	0	0
Gastrointestinal disorders
Constipation	0	0	0	0	0	1	0	1
Infections and infestations	0	0	0	1	0	1	1	1
Investigations (increases in ALT, AST, blood CPK and LDH, and transaminases); occult blood positive	2	2	0	0	0	0	2	2
Muscoskeletal and connective tissue disorders	0	0	0	0	0	1	0	1
Nervous system disorders
Dizziness	0	0	1	2	1	0	2	2
Headache	0	0	0	0	0	1	0	1
Haemorrhagic stroke	0	0	0	1	0	0	1	0
Paresthesia	0	0	0	1	0	0	1	0
Renal and urinary disorders	0	0	0	1	1	0	1	1
Skin and subcutaneous tissue disorders	0	0	0	1	0	0	1	0
Unspecified	0	0	0	0	0	1	0	1
Vascular disorders	0	0	0	2	2	0	2	2

AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; LDH, lactate dehydrogenase.